In preclinical studies, medications which decrease glutamate release have been shown to block some of the effects of psychostimulants. One such medication is riluzole, marketed for the treatment of Amyotrophic Lateral Sclerosis (ALS). The goal of this study was to determine riluzole's effects on acute physiological and subjective responses to D-amphetamine in healthy volunteers. Seven male and 5 female subjects participated in an outpatient double-blind, placebo-controlled, crossover study. Across 4 sessions, subjects were randomly assigned to a sequence of 4 oral treatments: placebo, 20 mg D-amphetamine alone, 100 mg riluzole alone, or D-amphetamine plus riluzole. Outcome measures included heart rate, blood pressure, plasma cortisol, performance on the Sustained Attention to Response Test (SART), and subjective measures. D-amphetamine increased heart rate, blood pressure and plasma cortisol levels while inducing psychostimulant-type subjective effects. On the SART, Damphetamine enhanced the speed of correct responses but also significantly increased the number of errors of commission. Riluzole at 100 mg did not block, the typical subjective and physiological responses to 20 mg D-amphetamine. Riluzole alone induced amphetamine-like subjective responses. On the SART test, riluzole increased the number errors of commission, but unlike D-amphetamine, did not speed reaction time. The mechanism accounting for these findings is unclear, but may involve processes other than decreased glutamate release by riluzole. The effects of glutamate medications on psychostimulant responses need to be further examined.
Introduction
Amphetamines are prototypical psychostimulants that produce a range of behavioral, cognitive, and physiological effects. In humans, amphetamines increase arousal, heart rate, blood pressure, and release of stress hormones as well as produce feelings of well-being, and decreasing appetite (Seiden et al., 1993) . In addition to their clinical use for treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy, amphetamines, especially methamphetamine, are also highly reinforcing and are commonly abused worldwide (Ahmad, 2003) . The reinforcing effects of amphetamines are thought to be mediated by activation of the mesocorticolimbic dopamine system, an essential component of the brain reward circuit (Bardo, 1998; Koob, 1992; Tzschentke, 2001) . As a result, amphetamines have been proposed to be useful tools to probe the brain reward circuit (Cardenas et al., 2002; Tremblay et al., 2002) . Changes in functioning of the brain reward system have been implicated in many neuropsychiatric conditions including major depression, schizophrenia and drug addiction.
A growing body of evidence suggests that glutamatergic transmission also contributes to the rewarding and addictive effects of psychostimulants (Kalivas et al., 2003) . For example, glutamatergic input to the ventral tegmental area (VTA) or nucleus accumbens increases dopaminergic transmission in the mesocorticolimbic pathway. Similarly, dopaminergic activation by repeated stimulant treatment increases glutamate release in the nucleus accumbens (Tzschentke and Schmidt, 2003) . Blockage of NMDA(N-methyl D-aspartate) or AMPA(α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) type glutamate receptors has 
